Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
Shi, W, Jiang, T, Nuciforo, P, Hatzis, C, Holmes, E, Harbeck, N, Sotiriou, C, Peña, L, Loi, S, Rosa, D D, Chia, S, Wardley, A, Ueno, T, Rossari, J, Eidtmann, H, Armour, A, Piccart-Gebhart, M, Rimm, DJournal:
Annals of Oncology
DOI:
10.1093/annonc/mdx805
Date:
April, 2018
File:
PDF, 42 KB
2018